Atea Pharmaceuticals (AVIR) CEO boosts stake via RSU vesting and 300,000-option exercise

Rhea-AI Filing Summary

Atea Pharmaceuticals President, CEO, and Chairman Jean-Pierre Sommadossi reported multiple equity award settlements and an option exercise. On January 31, 2026, 173,466 restricted stock units and 99,517 performance-based RSUs converted into common stock as previously granted awards fully vested.

Also on January 31, 2026, 106,093 shares of common stock were withheld at $4.24 per share to cover tax obligations, leaving 467,830 directly held shares. On February 3, 2026, he exercised a fully vested stock option for 300,000 shares at an exercise price of $1.24 per share, increasing his direct holdings to 767,830 shares. The filing also shows 5,866,025 shares held indirectly through JPM Partners LLC.

Insider Trade Summary

572,983 shares exercised/converted

Mixed 7 txns

Insider Sommadossi Jean-Pierre

Role President, CEO, and Chairman

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	300,000	$0.00	--
Exercise	Common Stock	300,000	$1.24	$372K
Exercise	Restricted Stock Units	173,466	$0.00	--
Exercise	Restricted Stock Units	99,517	$0.00	--
Exercise	Common Stock	272,983	$0.00	--
Tax Withholding	Common Stock	106,093	$4.24	$450K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 767,830 shares (Direct); Restricted Stock Units — 0 shares (Direct); Common Stock — 5,866,025 shares (Indirect, Held by JPM Partners LLC)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026. The option is fully vested and exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sommadossi Jean-Pierre

(Last) (First) (Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO, and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		M		272,983	A	(1)	573,923	D
Common Stock	01/31/2026		F		106,093	D	$4.24	467,830	D
Common Stock	02/03/2026		M		300,000	A	$1.24	767,830	D
Common Stock								5,866,025	I	Held by JPM Partners LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/31/2026		M			173,466	(2)	(2)	Common Stock	173,466	$0	0	D
Restricted Stock Units	(1)	01/31/2026		M			99,517(4)	(3)	(3)	Common Stock	99,517(4)	$0	0	D
Stock Option (Right to Buy)	$1.24	02/03/2026		M			300,000	(5)	12/08/2026	Common Stock	300,000	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.

3. Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.

4. Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026.

5. The option is fully vested and exercisable.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Atea Pharmaceuticals (AVIR) report for Jean-Pierre Sommadossi?

The Form 4 shows Jean-Pierre Sommadossi settling vested RSUs, exercising 300,000 stock options, and having shares withheld for taxes. These actions increased his direct common stock holdings while also disclosing a large indirect position through JPM Partners LLC.

How many Atea Pharmaceuticals shares did the CEO acquire through option exercise?

On February 3, 2026, the CEO exercised a fully vested stock option for 300,000 shares of Atea Pharmaceuticals common stock at an exercise price of $1.24 per share. This transaction increased his directly held common stock balance reported in the filing.

What RSU vesting activity was disclosed for Atea Pharmaceuticals (AVIR) on January 31, 2026?

The filing reports 173,466 RSUs and 99,517 performance-based RSUs settling into Atea common stock on January 31, 2026. These units were from a 520,400-RSU grant that vested in three annual installments and became fully vested as of that date.

Why were Atea Pharmaceuticals shares withheld at $4.24 in the Form 4?

On January 31, 2026, 106,093 Atea Pharmaceuticals common shares were surrendered at $4.24 per share. The filing indicates this transaction, coded “F,” represents shares withheld to satisfy tax obligations linked to the vesting and settlement of restricted stock units.

How many Atea Pharmaceuticals shares does the CEO hold directly and indirectly after these transactions?

After the reported transactions, Jean-Pierre Sommadossi directly holds 767,830 shares of Atea Pharmaceuticals common stock. The Form 4 also lists an additional 5,866,025 shares held indirectly through JPM Partners LLC, indicating a substantial associated ownership stake.

What do the Atea Pharmaceuticals Form 4 footnotes explain about the RSU awards?

The footnotes clarify that each RSU equals one Atea share, describe a 520,400-RSU grant vesting over three years, note satisfaction of performance criteria for certain RSUs, record a one-share rounding correction, and confirm the reported stock option is fully vested and exercisable.